EUVIMEDEUVIMED entdecken
Crossref

BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors

P. Li, Y. Zhu, Y. Guo, S. Wang

European Journal of Cancer · 2026-11 · 248 · 117475

DOI: 10.1016/j.ejca.2026.117475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026-11. Verfasst von P. Li und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Li, P., Zhu, Y., Guo, Y., & Wang, S. (2026). BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors. European Journal of Cancer, 248, 117475. https://doi.org/10.1016/j.ejca.2026.117475

Vancouver

Li P, Zhu Y, Guo Y, Wang S. BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors. European Journal of Cancer. 2026;248:117475. doi:10.1016/j.ejca.2026.117475

BibTeX
@article{Li2026,
  author = {Li, P. and Zhu, Y. and Guo, Y. and Wang, S.},
  title = {BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {248},
  pages = {117475},
  doi = {10.1016/j.ejca.2026.117475}
}
Kostenlos starten →